Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zonegran

- PMLiVE

Eisai sues DEA over Fycompa scheduling

Pharma company won FDA approval in 2012 but still lacks DEA verdict

EISAI

Eisai’s epilepsy drug Zonegran wins Swiss approval

Swissmedic licences new monotherapy indication for the treatment

- PMLiVE

Eisai pulls epilepsy drug Fycompa in Germany

Based on unfavourable assessment by pricing body

- PMLiVE

GSK/ Valeant’s Trobalt set for EU restrictions

Eye concerns prompt CHMP to recommend last-line use for the epilepsy drug

- PMLiVE

Sanofi invests €20m in Morocco

Will also collaborate with government on diabetes, mental health, epilepsy and pharma training

- PMLiVE

Eisai appoints Lynn Kramer chief clinical officer

Says newly created position will strengthen its research base

- PMLiVE

Pharma companies partner with Japanese government

GHIT Fund will support development of medicines for infectious diseases in developing countries

- PMLiVE

Eisai expands into Russia with Halaven launch

Breast cancer drug will be followed by epilepsy portfolio

EISAI

Eisai “appalled” at decision not to recommend Fycompa in Germany

Regulator says pharma company filed inadequate comparison data for its epilepsy drug

- PMLiVE

Early 2013 sees drug filings, launches and approvals in Japan

Includes medicines from Bayer, Takeda, Astellas and Eisai

EISAI

Eisai’s farletuzumab fails ovarian cancer trial

Unable to improve progression-free survival

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links